Regulatory
Sep 08, 2026 · 1 min read · 25,892 views
Compounder Empower receives FDA warning letter over GLP-1s
L
Liam Turner
Editorial · Sep 08, 2026
Reports indicate that the FDA has issued a warning letter to compounder Empower Pharmacy over its GLP-1 weight loss treatments. It's the third warning the Houston-based company has received in less than two years. In the
← Previous
ADARx targets $319M IPO as TRexBio, Retension join filing queue
Next →
Novo aims to diversify with new pipeline assets and bolt-on deals
